Full-Time

Clinical Trial Assistant II

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$75k - $90k/yr

Junior, Mid

San Carlos, CA, USA

Travel up to (~25%).

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in biological sciences or related health related field required.
  • 1 - 3 years of relevant experience in the pharmaceutical or biotech industry.
  • Excellent written and verbal communication skills.
  • Demonstrate proficiency in Microsoft Word, Excel and PowerPoint and other software platforms.
  • Demonstrated ability to multi-task, prioritize options.
  • Travel up to (~25%).
Responsibilities
  • Assisting in the development, review, distributing, and archiving of study specific documents and reports (plans, training materials, study guides, manuals, etc.)
  • Assisting with updating and maintaining clinical systems and any reporting tools.
  • Set up and maintenance of the trial master files (TMF) if applicable, or work with CRO to audit and resolve discrepancies.
  • Create, maintain, and track information for key study related activities.
  • Assisting in the preparation of meeting materials, scheduling meetings, and developing agendas, taking meeting minutes for internal clinical operation team meetings.
  • Gathering investigator and site information, to support study start-up, maintenance and close out activities.
  • Working with cross functional study teams, and vendors to assist in the coordination of clinical trial activities.
  • Support other clinical operations activities as appropriate.
Desired Qualifications
  • Preferably in clinical operations or clinical research-related experience.
  • Experience in oncology clinical trials.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a unique Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital, boosting financial stability.
  • $600M public stock offering shows strong investor confidence and funding for projects.
  • Recognition by the Lustgarten Foundation enhances their reputation in oncology.

What critics are saying

  • EQRx acquisition may lead to integration challenges and cultural clashes.
  • $600M stock offering could dilute existing shareholder value, causing dissatisfaction.
  • Focus on RAS-addicted cancers limits market scope and risks competition.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural product analogues.
  • Their Tri Complex Inhibitor platform targets RAS proteins, a critical cancer growth driver.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

7%
PRWeb
May 9th, 2025
The Lustgarten Foundation Honors Revolution Medicines For Transformative Research In Pancreatic Cancer

"Revolution Medicines exemplifies the power of bold science and collaboration in driving meaningful progress for patients," said Linda Tantawi, CEO of the Lustgarten Foundation

Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders